Literature DB >> 23288489

Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women.

Brendan M Everett1, Nancy R Cook, Daniel I Chasman, Maria C Magnone, Maria Bobadilla, Nader Rifai, Paul M Ridker, Aruna D Pradhan.   

Abstract

BACKGROUND: Animal data suggest that natriuretic peptides play an important role in energy metabolism, but prospective studies evaluating a relationship between these peptides and type 2 diabetes mellitus (T2DM) in humans are few and results are conflicting.
METHODS: We used a prospective case-cohort approach (n = 491 T2DM cases, n = 561 reference subcohort) within the Women's Health Study to evaluate baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations and the risk of incident T2DM. We also tested for associations between 4 common variants in the natriuretic peptide A and B genes (NPPA and NPPB) and NT-proBNP concentrations (n = 458) and incident T2DM (n = 1372 cases among 22 607 women).
RESULTS: Case subjects had higher median baseline body mass index (29.4 vs 25.0 kg/m(2), P < 0.001) and lower baseline median (interquartile range) NT-proBNP concentrations [46.8 ng/L (26.1-83.2) vs 66.7 ng/L (39.3-124.7), P < 0.001]. In proportional hazards models adjusting for established diabetes risk factors, women in the highest quartile of baseline NT-proBNP concentration (≥ 117.4 ng/L) had a 49% reduction in risk of T2DM [hazard ratio (HR) 0.51, 0.30-0.86, P = 0.01] relative to those in the lowest quartile. Two of the 4 tested variants in NPPA and NPPB (rs632793, rs198389) were associated with increased NT-proBNP concentrations and reduced risk of T2DM. For example, each copy of the minor allele of rs632793 was associated with increased NT-proBNP [β (SE) = 0.201 (0.063), P < 0.01] and decreased T2DM risk (HR 0.91, 0.84-0.989, P = 0.026).
CONCLUSIONS: NT-proBNP concentrations that are high, but still within the reference interval, associate with reduced risk of incident diabetes in women and support a favorable role for natriuretic peptides in the prevention of T2DM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23288489      PMCID: PMC3694412          DOI: 10.1373/clinchem.2012.194167

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  30 in total

1.  A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community.

Authors:  Valentina Cannone; Guido Boerrigter; Alessandro Cataliotti; Lisa C Costello-Boerrigter; Timothy M Olson; Paul M McKie; Denise M Heublein; Brian D Lahr; Kent R Bailey; Maurizio Averna; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2011-08-02       Impact factor: 24.094

2.  The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic beta-cell function.

Authors:  Ana B Ropero; Sergi Soriano; Eva Tudurí; Laura Marroquí; Noelia Téllez; Birgit Gassner; Pablo Juan-Picó; Eduard Montanya; Ivan Quesada; Michaela Kuhn; Angel Nadal
Journal:  Endocrinology       Date:  2010-06-16       Impact factor: 4.736

3.  A map of human genome variation from population-scale sequencing.

Authors:  Gonçalo R Abecasis; David Altshuler; Adam Auton; Lisa D Brooks; Richard M Durbin; Richard A Gibbs; Matt E Hurles; Gil A McVean
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

4.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

Authors:  Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

5.  Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure.

Authors:  Christopher Newton-Cheh; Martin G Larson; Ramachandran S Vasan; Daniel Levy; Kenneth D Bloch; Aarti Surti; Candace Guiducci; Sekar Kathiresan; Emelia J Benjamin; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Stefan Blankenberg; Frank Kee; Peter Nilsson; Xiaoyan Yin; Leena Peltonen; Erkki Vartiainen; Veikko Salomaa; Joel N Hirschhorn; Olle Melander; Thomas J Wang
Journal:  Nat Genet       Date:  2009-02-15       Impact factor: 38.330

6.  Thirty-one novel biomarkers as predictors for clinically incident diabetes.

Authors:  Veikko Salomaa; Aki Havulinna; Olli Saarela; Tanja Zeller; Pekka Jousilahti; Antti Jula; Thomas Muenzel; Arpo Aromaa; Alun Evans; Kari Kuulasmaa; Stefan Blankenberg
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

7.  The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects.

Authors:  Hélène Choquet; Christine Cavalcanti-Proença; Cécile Lecoeur; Christian Dina; Stéphane Cauchi; Martine Vaxillaire; Samy Hadjadj; Fritz Horber; Natasha Potoczna; Guillaume Charpentier; Juan Ruiz; Serge Hercberg; Suliya Maimaitiming; Ronan Roussel; Michael Boenhnke; Anne U Jackson; Wolfgang Patsch; Franz Krempler; Benjamin F Voight; David Altshuler; Leif Groop; Gudmar Thorleifsson; Valgerdur Steinthorsdottir; Kari Stefansson; Beverley Balkau; Philippe Froguel; David Meyre
Journal:  Hum Mol Genet       Date:  2009-04-18       Impact factor: 6.150

8.  Rapid regulation of K(ATP) channel activity by 17{beta}-estradiol in pancreatic {beta}-cells involves the estrogen receptor {beta} and the atrial natriuretic peptide receptor.

Authors:  Sergi Soriano; Ana B Ropero; Paloma Alonso-Magdalena; Cristina Ripoll; Ivan Quesada; Birgit Gassner; Michaela Kuhn; Jan-Ake Gustafsson; Angel Nadal
Journal:  Mol Endocrinol       Date:  2009-10-23

9.  Analyses and comparison of accuracy of different genotype imputation methods.

Authors:  Yu-Fang Pei; Jian Li; Lei Zhang; Christopher J Papasian; Hong-Wen Deng
Journal:  PLoS One       Date:  2008-10-29       Impact factor: 3.240

10.  Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity.

Authors:  Kazutoshi Miyashita; Hiroshi Itoh; Hirokazu Tsujimoto; Naohisa Tamura; Yasutomo Fukunaga; Masakatsu Sone; Kenichi Yamahara; Daisuke Taura; Megumi Inuzuka; Takuhiro Sonoyama; Kazuwa Nakao
Journal:  Diabetes       Date:  2009-08-18       Impact factor: 9.461

View more
  10 in total

1.  Changes in N-terminal pro-B-type natriuretic peptide and incidence of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  O A Sanchez; D A Duprez; H Bahrami; C A Peralta; L B Daniels; J A Lima; A Maisel; A R Folsom; D R Jacobs
Journal:  Diabetes Metab       Date:  2015-06-03       Impact factor: 6.041

2.  Computerized tomography measured liver fat is associated with low levels of N-terminal pro-brain natriuretic protein (NT-proBNP). Multi-Ethnic Study of Atherosclerosis.

Authors:  Otto A Sanchez; Mariana Lazo-Elizondo; Irfan Zeb; Russell P Tracy; Ryan Bradley; Daniel A Duprez; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; David R Jacobs; Mathew J Budoff
Journal:  Metabolism       Date:  2016-02-27       Impact factor: 8.694

3.  Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: The cardiovascular health study.

Authors:  Erika F Brutsaert; Mary L Biggs; Joseph A Delaney; Luc Djoussé; John S Gottdiener; Joachim H Ix; Francis Kim; Kenneth J Mukamal; David S Siscovick; Russell P Tracy; Ian H de Boer; Christopher R deFilippi; Jorge R Kizer
Journal:  Metabolism       Date:  2016-06-24       Impact factor: 8.694

4.  Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations.

Authors:  Pratyaksh K Srivastava; Aruna D Pradhan; Nancy R Cook; Paul M Ridker; Brendan M Everett
Journal:  Am J Cardiol       Date:  2015-11-18       Impact factor: 2.778

Review 5.  INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist.

Authors:  Hugo R Ramos; Andreas L Birkenfeld; Adolfo J de Bold
Journal:  Endocr Connect       Date:  2015-09       Impact factor: 3.335

6.  Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis.

Authors:  Pratyaksh K Srivastava; Aruna D Pradhan; Nancy R Cook; Paul M Ridker; Brendan M Everett
Journal:  J Am Heart Assoc       Date:  2017-12-23       Impact factor: 5.501

Review 7.  Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control.

Authors:  Jelena P Seferovic; Scott D Solomon; Ellen W Seely
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-25       Impact factor: 3.565

8.  STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure.

Authors:  Valentina Cannone; Mark Ledwidge; Chris Watson; Paul M McKie; John C Burnett; Kenneth McDonald
Journal:  JACC Basic Transl Sci       Date:  2021-06-16

9.  Six-year changes in N-terminal pro-brain natriuretic peptide and changes in weight and risk of obesity.

Authors:  Mariana Sbaraini da Silva; Mariana Lazo; Natalie R Daya; Olive Tang; Beatriz D Schaan; Christie M Ballantyne; Chiadi Ndumele; Elizabeth Selvin
Journal:  Obesity (Silver Spring)       Date:  2021-07       Impact factor: 9.298

10.  Opposing Associations of NT-proBNP With Risks of Diabetes and Diabetes-Related Complications.

Authors:  Anna Birukov; Fabian Eichelmann; Olga Kuxhaus; Elli Polemiti; Andreas Fritsche; Janine Wirth; Heiner Boeing; Cornelia Weikert; Matthias B Schulze
Journal:  Diabetes Care       Date:  2020-08-17       Impact factor: 19.112

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.